Acquired immunodeficiency syndrome (AIDS), caused by the human immunodeficiency
virus (HIV), has become a heavy burden of disease and an important public health problem …

Background Meeting the challenge of antiretroviral therapy (ART) whose efficacy can last a
lifetime requires continuous updating of the virological, pharmacological, and quality of life …

Background Genotypic resistance testing (GRT) is routinely performed upon diagnosis of
HIV-1 infection or during virological failure using plasma viral RNA. An alternative source for …

Background We aimed at evaluating the temporal trend of drug-resistance and APOBEC
editing from HIV-DNA genotypic resistance tests (GRT) in virologically suppressed …

The human immunodeficiency virus (HIV) was unknown until the early 1980's when
increasing numbers of cases of unusual opportunistic infections and Kaposi sarcoma in …

The TANGO study (ClinicalTrials. gov, NCT03446573) demonstrated that switching to
dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide …

Approximately 35% of persons with diagnosed HIV infection in the United States do not have
a suppressed viral load (Centers for Disease Control and Prevention, 2022), underscoring …

Background With the success of antiretroviral therapy (ART), children born with HIV are
more likely to reach adolescence. However, frequent non‐adherence to ART in adolescents …

Availability of long-acting, injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) was eagerly
anticipated, but uptake remains sluggish. Most clinics have encountered numerous hurdles …

Objective HIV DNA sequencing is now routinely used for HIV-infected individuals on
antiretroviral therapy (ART) with or without partial genotypic history. Successful amplification …